

In Hyperphosphatemia

Recommend,

SEVLAREN

Sevelamer Carbonate Tablets 400 mg / 800 mg

La Renon®



Indication -

SEVLAREN (sevelamer carbonate) is indicated for the control of hyperphosphataemia in adult patients receiving hemodialysis or peritoneal dialysis, and with chronic kidney disease not on dialysis with serum phosphorus ≥1.78 mmol/L

Mechanism of Action-

SEVLAREN contains sevelamer carbonate, a non-absorbed phosphate-binding crosslinked polymer, free of metal and calcium. It contains multiple amines separated by 1 carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By binding phosphate in the dietary tract and decreasing absorption, sevelamer carbonate lowers the phosphate concentration in the serum.

Dosage -

SEVLAREN is taken as 800 mg to 1600 mg orally three times daily with each meal based on serum phosphorus level:

- 1. Phosphorus greater than 5.5 and less than 7.5 mg/dL = 800 mg
- 2. Phosphorus greater than or equal to 7.5 and less than 9.0 mg/dL = 1600 mg
- 3. Phosphorus greater than or equal to 9.0 mg/dL = 1600 mg

Presentation – SEVLAREN is available as Film Coated tablet in 400 mg and 800 mg strengths.

La Renon Healthcare

208-ISCON Elegance | Circle P | Prahlad Nagar Cross Roads S.G.Highway | Ahmedabad - 380051 | Gujarat | India. Phone: +91-79-3046-1000 (30 Lines) | Fax: +91-79-3046-1001 E-Mail: info@larenon.com | www.larenon.com

l am	
Call me on	
Mail me at	